文献速递脊柱关节炎

外周脊柱关节炎疾病活动度仪器的测量性能:CRESPA 试验的事后分析

Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial.
PubMed 文献 · RMD Open · 2025-07-15

该研究为 CRESPA 随机对照试验的事后分析,纳入 60 例早期活动性外周脊柱关节炎患者(戈利木单抗组 40 例,安慰剂组 20 例),评估多种疾病活动度仪器的结构效度与区分能力。结果显示复合指标(DAPSA、BASDAI、ASDAS)结构效度更优,临床缓解定义是最具区分力的应答标准。

要点

  • 复合指标(DAPSA、BASDAI、ASDAS)在活动与非活动患者间的结构效度优于单一指标。
  • 复合指标和整体评估(PGA、PhGA)的纵向结构效度一致良好。
  • 临床试验区分度在复合指标、整体评估和关节计数中均良好,临床缓解定义区分力最强。

核心结论

  • 复合指标和整体评估在外周脊柱关节炎中均表现良好,但 DAPSA、ASDAS 和 BASDAI 等复合评分的结构效度更优。
  • 临床缓解定义(无关节炎、附着点炎和指趾炎)是最具区分力的应答标准。

研究设计与样本

  • CRESPA 随机对照试验的事后分析,纳入早期活动性外周脊柱关节炎患者,随机分配至戈利木单抗组或安慰剂组,使用至第 12 周的安慰剂对照部分数据。
  • 共纳入 60 例患者(戈利木单抗组 40 例,安慰剂组 20 例)。

主要发现

  • 结构效度(已知组区分,以标准化均值差 SMD 评估)在复合指标(DAPSA、BASDAI、ASDAS)中表现更好,活动与非活动患者间 SMD 更高。
  • 纵向结构效度(标准化应答均值和效应量)在复合指标(如 ASDAS、DAPSA)和整体评估(PGA、PhGA)中一致良好。
  • 临床试验区分度(SMD)在复合指标(BASDAI、ASDAS、DAPSA)、整体评估(PGA、PhGA)和关节计数(SJC66、TJC68)中良好。
  • 在二分类结局中,临床试验区分度最强的是临床缓解(即无关节炎、附着点炎和指趾炎)、BASDAI50、DAPSA-低疾病活动度(LDA)和 ASDAS-LDA。

关键数值与推荐

  • 结构效度以活动与非活动患者间的标准化均值差(SMD)评估,复合指标(DAPSA、BASDAI、ASDAS)的 SMD 更高。
  • 纵向结构效度以标准化应答均值和效应量评估,复合指标和整体评估一致良好。
  • 临床试验区分度以 SMD 评估,复合指标、整体评估和关节计数良好;二分类结局中临床缓解定义区分力最强。

临床怎么用

  • 在外周脊柱关节炎临床研究中,可优先选用 DAPSA、ASDAS 或 BASDAI 等复合指标评估疾病活动度。
  • 临床缓解定义(无关节炎、附着点炎和指趾炎)可作为区分治疗应答的优选应答标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unravelling the performance of disease activity measures in peripheral spondyloarthritis (pSpA) is crucial for the development of clinical studies. We aimed to evaluate the construct validity and discriminatory capacity of various instruments assessing disease activity and response criteria in patients with pSpA. METHODS: Post-hoc analysis of the CRESPA randomised controlled trial including patients with early active pSpA. Patients were randomised to golimumab (GOL) or placebo (PBO). Data of the placebo-controlled part until week 12 were used. Construct validity (known group discrimination assessed with standardised mean difference, SMD) in the 12-week data, longitudinal construct validity (ie, standardised response mean and effect size) and trial discrimination (SMD) of several disease activity instruments were assessed. As part of trial discrimination, a χ2 test was performed for binary outcomes. RESULTS: A total of 60 patients (40 GOL, 20 PBO) were included. Construct validity was better for composite outcomes (ie, Disease Activity in Psoriatic Arthritis (DAPSA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Axial Spondyloarthritis Disease Activity Score (ASDAS)-higher SMD between active and inactive patients). Longitudinal construct validity was consistently good for composite outcomes (eg, ASDAS, DAPSA) and global assessments (Patient Global Assessment (PGA), Physician Global Assessment (PhGA)). Clinical trial discrimination was good for composites (BASDAI, ASDAS, DAPSA), global assessments (PGA, PhGA) and joint counts (swollen joint count (SJC66) and tender joint count (TJC68)).Among binary outcomes, trial discrimination was strongest for clinical remission (ie, absence of arthritis, enthesitis and dactylitis), BASDAI50, DAPSA-Low Disease Activity (LDA) and ASDAS-LDA. CONCLUSION: While both composite and global outcome measurement instruments performed well in pSpA, composite scores like DAPSA, ASDAS and BASDAI showed better construct validity. The clinical remission definition was the most discriminatory response criterion.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. López-Medina C, Capelusnik D, Webers C, et al. Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial. RMD Open. 2025. PMID: 40664470. doi:10.1136/rmdopen-2025-005525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。